Form 4: Greenwich LifeSciences CEO Patel Acquires 5,400 Shares of Common Stock
SEC Form 4 Filing
Snehal Patel, CEO and CFO of Greenwich LifeSciences, reports the acquisition of 5,400 shares of common stock at $8.98 per share on April 17, 2025.
Summary
- On April 17, 2025, Snehal Patel, the CEO and CFO of Greenwich LifeSciences, acquired 5,400 shares of common stock.
- The purchase price was $8.98 per share.
- Following the transaction, Patel directly owns 5,567,002 shares of Greenwich LifeSciences common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally seen as a positive sign, indicating confidence in the company's prospects, but the impact is limited without additional context.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 04/17/2025 | Date of transaction: Snehal Patel acquired 5,400 shares of common stock. |
| 04/22/2025 | Date of signature on the Form 4 filing. |
Keywords
Greenwich LifeSciences, GLSI, Snehal Patel, stock acquisition, Form 4, beneficial ownership, CEO, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.